There are currently 48 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Autism participants are Texas, California, New York and Tennessee.
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500
Recruiting
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Sharp Memorial Hospital, San Diego, California +32 locations
Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Register for Updates
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
NCT05327946
Recruiting
This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study. The purpose of this study is to find the highest dose of BI 770371 that people with advanced cancer can tolerate when taken alone or together with a medicine called ezabenlimab. BI 770371 and ezabenlimab are antibodies that may help the immune system fight cancer (checkpoint inhibitors). In this study, BI 7703... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Florida Cancer Specialists, Sarasota, Florida +4 locations
Conditions: Solid Tumors
Register for Updates
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
NCT05387265
Recruiting
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Sarah Cannon Research Institute, LLC, Nashville, Tennessee +3 locations
Conditions: Solid Tumors
Register for Updates
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
All
Ages:
All
Trial Updated:
04/10/2024
Locations: Southern Cancer Center, Daphne, Alabama +166 locations
Conditions: Solid Tumors
Register for Updates
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +30 locations
Conditions: Solid Tumors
Register for Updates
Screening Study for Participants With Malignant Tumors
NCT05419375
Recruiting
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +123 locations
Conditions: Solid Tumors
Register for Updates
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324
Recruiting
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +29 locations
Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
NCT03366116
Recruiting
Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
03/28/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Solid Tumors
Register for Updates
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
NCT02379416
Recruiting
Background: - Researchers want to find better ways to treat cancer. One drug that treats cancer is paclitaxel. Sometimes proteins block that drug from working. Researchers want to see if another drug, nilotinib, helps paclitaxel work better. Objective: - To test the safety of nilotinib plus paclitaxel and find out what doses of the drugs can be given safely to people. Eligibility: - Adults at least 18 years old with advanced cancer that has progressed after receiving standard treatment, or... Read More
Gender:
All
Ages:
Between 12 years and 120 years
Trial Updated:
03/28/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Solid Tumors
Register for Updates
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448
Recruiting
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +15 locations
Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Register for Updates
QTX3034 in Patients With KRAS G12D Mutation
NCT06227377
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: South Texas Accelerated Research Therapeutics, San Antonio, Texas +2 locations
Conditions: Solid Tumors
Register for Updates
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
NCT05101070
Recruiting
The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Angeles Clinic and Research Center, Los Angeles, California +5 locations
Conditions: Solid Tumors
Register for Updates